Latest Infliximab Stories
The latest regional Outpatient Infusion Center officially opened this week at Stafford Hospital, Mary Washington Healthcare. Stafford, VA (PRWEB) June 22, 2012
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint of ACR20 response at week 12 than those on placebo: 58% on CZP200mg Q2W; and 51.9% on CZP 400 mg Q4W compared to 24.3% on placebo.
New research being presented at Digestive Disease Week® (DDW) offers key insights into the prevention and treatment of bowel diseases, which affect millions of people worldwide.
The American College of Rheumatology (ACR) has released the 2012 recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in the treatment of rheumatoid arthritis (RA).
- totally perplexed and mixed up.